Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RMC-5127 · 1 trial · 10 indications
Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5
Number of patients with changes from baseline in vital signs
Number of patients with changes from baseline in ECG test values
Number of patients with changes from baseline in clinical laboratory test values
Number of patients with dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| Arm A: RMC-5127 Monotherapy | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Arm B: RMC-5127 + Daraxonrasib Combination | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Arm C: RMC-5127 + Cetuximab Combination | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| RMC-5127 | DRUG | oral tablets |
| daraxonrasib | DRUG | oral tablets |
| cetuximab | DRUG | IV infusion |
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy. * Received and progressed or been intolerant...
RMC-5127 is an investigational small molecule developed by Revolution Medicines, Inc. for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC). It is a RAS(ON) G12V inhibitor currently in Phase 1 clinical development and is not yet approved for any indication.
RMC-5127 is being studied for use in non-small cell lung cancer (NSCLC) and other advanced solid tumors that carry a KRAS G12V mutation. It is an investigational therapy in Phase 1 testing and has not been approved for the treatment of NSCLC or any other cancer.
RMC-5127 targets RAS(ON) G12V, the active, GTP-bound form of the KRAS G12V mutant protein. By binding this RAS(ON) state, the small molecule is designed to inhibit signaling driven by the G12V mutation. The trial enrolls patients whose tumors are biomarker-selected for KRAS G12V.
RMC-5127 is developed by Revolution Medicines, Inc., a clinical-stage oncology company that trades on the Nasdaq under the ticker RVMD. Revolution Medicines is running the Phase 1 study of RMC-5127 in the United States.
RMC-5127 is in Phase 1 clinical development. It has one active, recruiting Phase 1 trial and no completed trials. RMC-5127 is investigational and has not received FDA approval for any indication.
RMC-5127 is being evaluated in the Phase 1 trial NCT07349537, titled Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors. The trial is recruiting in the United States, has an estimated enrollment of 574 participants, and enrolls adults 18 years and older with advanced solid tumors.